Evaluation of the Effectiveness of Risk Minimization Measures: A Survey Among Pharmacists to Assess the Impact of the RMP Material for Patients on Promoting the Proper use of NINLARO in Japan

Study identification

• EU PAS number:
  EUPAS104398
• Study ID:
  105390
• Official title and acronym:
  Evaluation of the Effectiveness of Risk Minimization Measures: A Survey Among Pharmacists to Assess the Impact of the RMP Material for Patients on Promoting the Proper use of NINLARO in Japan
• DARWIN EU® study:
  No
• Study countries:
  Japan
• Study description:
  This is a survey among pharmacists who have instructed NINLARO therapy in ixazomib, lenalidomide and dexamethasone (IRD) dosing to patients with relapsed/refractory multiple myeloma (rrMM). ; The main aims of the study are: ; • To assess the frequency of pharmacists who have provided patients with the contents of the RMP material for patients. ; • To assess the frequency of pharmacists who have obtained the RMP material for patients. ; • To evaluate the depth of understanding of proper usage of NINLARO among pharmacists.
• Study status:
  Finalised

Research institutions and networks

Institutions

Takeda

Study timelines

Date when funding contract was signed

Actual: 31/01/2023

Study start date

Planned: 01/06/2023

Actual: 01/06/2023

Data analysis start date

Planned: 12/06/2023

Actual: 12/06/2023

Date of final study report

Planned: 01/06/2024

Actual: 23/10/2023

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Takeda

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable